Account
White page
Your Shopping Cart is Empty

     
HEART HEALTH COMPLETE

 

Supports healthy blood clotting
Promotes healthy whole blood viscosity
Improves overall circulation
Keeps blood cells from sticking together
Maintains blood pressure levels already within normal range
More effective: 20% better efficacy
Better absorbed: 10% better lymphatic absorption
Superior strain: Derived from the powerful Naruse (N) strain
Standardized: Standardized for potency utilizing the IU test for activity — not FU
Non-GMO: Derived from ORGANIC NON-GMO soybeans
Hypoallergenic: Contains no corn-derived stabilizers

z 

NATTO  Japanese Superfood Natto naturally contains the enzyme nattokinase, discovered by Dr. Hiroyumi Sumi in 1980. Several published studies have shown that nattokinase promotes healthy blood clotting and normal blood viscosity, which helps blood flow more easily through the veins. Yet not all nattokinase is the same.

 

THE STORY OF NATTOKINASE  In 1980, Dr. Sumi was doing research at the University of Chicago to find a substance that could help maintain the body’s normal fibrinolytic activity, or ability to break down blood clots. One day he was eating his lunch — a traditional Japanese dish made from fermented soybeans called natto — when inspiration struck. He decided to test the fibrinolytic activity of natto. To his surprise, it turned out to have the best fibrinolytic activity of the nearly 200 foods he had tested. He isolated the enzyme responsible and named it nattokinase. 

 

HEART DISEASE  Nattokinase may be potentially useful as a clot-buster and blood thinner, and is considered by some in the alternative medicine community as a possible adjunctive therapy in cardiovascular disease. There is some evidence for its effectiveness. Possible side effects have been reported. In one case, a patient concurrently taking aspirin and 400 mg of nattokinase daily for seven consecutive days to prevent stroke suffered an acute cerebellar hemorrhage.

 

ALZHEIMER'S DISEASE  2009 study showed that nattokinase may be effective in catabolism of toxic amyloid fibrils associated with Alzheimer's Disease, as well as the insulin fibrils associated with diabetes and the prion peptide fibrils associated with prion diseasesThe study reported that its effects were similar to those seen when proteinase K was applied in the same manner. The study's authors noted that "[t]his amyloid-degrading ability of nattokinase suggests that it may be useful in the treatment of amyloid-related diseases," particularly as "[p]revious results in rats, dogs and humans have suggested that nattokinase can enter the circulation when taken orally." However, they cautioned that their results were preliminary, and made the following suggestion:"[S]ince natto has been ingested by humans for a long time, it would be worthwhile to carry out an epidemiological study on the rate of occurrence of various amyloid-related diseases in a population regularly consuming natto." Indeed, 2011 WHO data shows nearly a tenfold increased incidence of death by Alzheimer's and dementia in the United States versus Japan, where natto is regularly consumed by a significant portion of the populace. 

Since 
Bacillus subtilis depends heavily on amyloid proteins for its cellular structure, nattokinase may be most effective in the presence of live B. subtilis, which sequesters such proteins in its cell membrane. This compounds the difficulty of conducting in vivo efficacy studies on nattokinase isolate, as it is unclear what portion of nattokinase's effect stems from activity in the gastrointestinal tract versus once it enters circulation.

 

 
















                                                                                                                                                                                                                               NEW NATTOKINASE INFORMATION

 HEART HEALTH COMPLETE  utilizes a new standardization for fibrinolytic activity which is more sensitive and specific to nattokinase activity. Originally, the Fibrin Unit (FU) method was created for the sake of convenience. Because fibrin, which is insoluble in water, is used as the substrate, accurate measurement of the enzyme reaction is not possible through this method. Therefore, to accurately measure the potency of Heart Health Complete, International Units (IU) are required to quantify the results of the enzyme activity.


HEART HEALTH COMPLETE  incorporates a new strain (“strain N”) of Bacilius Substilisin that produces higher activity than other strains. In particular, the cultured solution of the Journey Heart Health (N strain), displayed activity that was 17.9 times greater that of the control. Furthermore, fibrinolytic activity was also observed in the bacteria itself, and the activity on the N strain elevated to a level that was 70 times as much as the control. The therapeutic benefit of this type of activity on human cells is the promotion of the release of tissue-plasminogen activator (t-PA). t-PA is a protein involved in the breakdown of blood clots – it catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown.

IN ADDITION to t-PA,  Heart Health Complete has demonstrated a new mechanism of action involving fibrinolytic pharmacokinetics. This new strain of nattokinase has shown for the first time that is has a higher kinin-producing capacity than plasma kininogen. The physiological activities of kinin (and its products like bradykinin) include lowering blood pressure, promotion of capillary permeability, local vasodilation, smooth muscle contraction, promotion of lymph flow, and inflammatory modulation. This kinin-producing activity is involved in the circulatory systems of all internal organs.

HEART HEALTH COMPLETE'S  hypotensive and circulation-improving effects have the potential to replace other more invasive and ADR-promoting medications in the conventional and alternative marketplace.

ANOTHER NOVEL CHARACTERISTIC  of Heart Health Complete is its anti-viscogenic effect. No other natural substance has demonstrated the ability to quantitatively lower blood viscosity as Heart Health Complete has. The applications of this attribute alone make it one of the most useful therapies in even the most serious cardiovascular conditions.

LASTLY,  unlike other commercial sources of nattokinase, Heart Health Complete incorporates a non-corn source of maltodextrin, making it the most hypoallergenic source of nattokinase on the market.